Celsion (CLSN) Downgraded to Sell at ValuEngine

ValuEngine downgraded shares of Celsion (NASDAQ:CLSN) from a hold rating to a sell rating in a report issued on Wednesday morning.

Separately, Zacks Investment Research cut Celsion from a buy rating to a hold rating in a research report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $11.90.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:CLSN opened at $2.24 on Wednesday. Celsion has a fifty-two week low of $1.24 and a fifty-two week high of $6.06. The firm has a market capitalization of $39.74, a price-to-earnings ratio of -0.94 and a beta of 1.80.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC acquired a new position in Celsion Co. (NASDAQ:CLSN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion as of its most recent filing with the Securities and Exchange Commission (SEC). 3.84% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/03/31/celsion-clsn-downgraded-to-sell-at-valuengine.html.

Celsion Company Profile

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply